ISO 4217 Numeric Code
(redirected from 052)ISO 4217 Numeric Code
A code used especially when financial transactions are made using non-Latin alphabets or scripts.
Farlex Financial Dictionary. © 2012 Farlex, Inc. All Rights Reserved
References in periodicals archive
?
Du is supporting the auction by putting up numbers 052 3333333, 052 5222222, 052 2222223, 052 5555554, and 052 4444442.
OK Trans Taxi: 052 500 500; Mobile: 0886 388 388; 0899 388 388
Varna Taxi: 052 666 666; Mobile: 0884 666 600; 0895 666 600
Biopharmaceutical company Anacor Pharmaceuticals (Nasdaq:ANAC) announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract by the US Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.
The company said that this contract provides up to USD94m in funding for up to four years to support studies to evaluate the efficacy of GSK '052 against bioterrorism threats, Phase 2 clinical trials for ventilator-associated pneumonia, and Phase 3 trials for complicated intra-abdominal infections.
M2 PHARMA-March 23, 2011-XOMA 052 Phase IIb trial does not achieve primary endpoint(C)2011 M2 COMMUNICATIONS
23 March 2011 - US-based novel antibody therapeutics developer XOMA Ltd (NASDAQ: XOMA) announced yesterday that its Phase IIb trial of XOMA 052 in Type 2 diabetes did not achieve the primary endpoint of reduction in glycosylated hemoglobin, or HbA1c, after six monthly treatments with XOMA 052 compared to placebo.
(Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, and Les Laboratoires Servier (Servier), France's largest privately-held pharmaceutical company, has announced the signing of a regional agreement to jointly develop and commercialize XOMA 052, XOMA's anti-inflammatory drug candidate, in multiple indications.
Customers can call the helpline on 0800 052 0037 throughout the Christmas and New Year period.
(Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, has announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.
29 September 2010 - US therapeutic antibodies maker and developer XOMA Ltd (NASDAQ: XOMAD) said today that patient enrollment was recently completed for its Phase IIa trial of XOMA 052 in patients with Type 2 diabetes.
M2 PHARMA-August 4, 2010-XOMA 052 gains Orphan Drug status by FDA for Behcet's disease(C)2010 M2 COMMUNICATIONS
Financial browser
?
- ▲
- "Cannot complete"
- "Clean your skirts"
- "Confirm me out"
- "Cost me"
- "Customer picking prices"
- "Dual-Apper"
- "How are you making XXX?"
- "It's us,"
- "Just me asking"
- "Kick it out"
- "More behind it"
- "Need the tick"
- "News out"
- "No Autex"
- "O.K. to cross"
- "Participate but do not initiate"
- "Put it on "
- "Put pants on it "
- "Ring the cash register"
- "Send it in"
- "Soft" capital rationing
- "Static" Return
- "Take it down"
- "Take me along"
- "Trade me out"
- 052
- 1/f Noise
- 10% guideline
- 100% Loan
- 1031 exchange
- 1040 form
- 1040A Form
- 1040EZ Form
- 1040PC Form
- 1099
- 1099 B
- 1099 DIV
- 1099 Income
- 1099-DIV
- 1099-INT
- 1099-OID
- 10-K
- 10-Q
- 10-year Averaging
- 10-Year Treasury Note
- 11th District Cost of Funds Index
- 12 MTA
- 125% Loan
- 12b-1 fee
- 12B-1 fees
- 12B-1 Fund
- ▼
Full browser
?